---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-007402"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T00:22:51.042464+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acadia Q1 NUPLAZID sales $115.5M (+8% YoY); net loss widens to $113.1M on $60M Stoke payment

## Summary
- Q1 NUPLAZID net sales $115.5M (+8% vs $106.6M Q1 2021); net loss $113.1M ($0.70/sh) vs $66.4M loss in prior year.
- R&D expense surged to $128.9M from $57.0M, driven by $60M upfront payment to Stoke Therapeutics under license deal.
- Cash and investments $446.0M at March 31, 2022, down from $520.7M at Dec 31, 2021.
- FY2022 NUPLAZID net sales guidance reiterated at $510-$560M; FDA AdComm for pimavanserin in ADP set for June 17, 2022.
- Trofinetide NDA for Rett syndrome on track for mid-2022; Parag Meswani and Holly Valdiviez joined as senior commercial leads.

## SEC filing metadata
- accession: 0000950170-22-007402
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000095017022007402/0000950170-22-007402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000095017022007402/acad-20220504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-007402
- JSON: https://secwatch.observer/filing/0000950170-22-007402.json
- Plain text: https://secwatch.observer/filing/0000950170-22-007402.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.